Development of Alendronate-conjugated Poly (lactic-co-glycolic acid)-Dextran Nanoparticles for Active Targeting of Cisplatin in Osteosarcoma

Ping Liu¹, Liang Sun², Dong-sheng Zhou³, Peng Zhang³, Yong-hui Wang³, Dong Li³, Qing-hu Li³ & Rong-jie Feng³

In this study, we developed a novel poly (lactic-co-glycolic acid)-dextran (PLD)-based nanodelivery system to enhance the anticancer potential of cisplatin (CDDP) in osteosarcoma cells. A nanosized CDDP-loaded PLGA-DX nanoparticle (PLD/CDDP) controlled the release rate of CDDP up to 48 h. In vitro cytotoxicity assay showed a superior anticancer effect for PLD/CDDP and with an appreciable cellular uptake via endocytosis-mediated pathways. PLD/CDDP exhibited significant apoptosis of MG63 cancer cells compared to that of free CDDP. Approximately ~25% of cells were in early apoptosis phase after PLD/CDDP treatment comparing to ~15% for free CDDP after 48 h incubation. Similarly, PLD/CDDP exhibited ~30% of late apoptosis cells comparing to only ~8% for free drug treatment. PLD/CDDP exhibited significantly higher G2/M phase arrest in MG63 cells than compared to free CDDP with a nearly 2-fold higher arrest in case of PLD/CDDP treated group (~60%). Importantly, PLD/CDDP exhibited a most significant anti-tumor activity with maximum tumor growth inhibition. The superior inhibitory effect was further confirmed by a marked reduction in the number of CD31 stained tumor blood vessels and decrease in the Ki67 staining intensity for PLD/CDDP treated animal group. Overall, CDDP formulations could provide a promising and most effective platform in the treatment of osteosarcoma.

Osteosarcoma (OS) is one of most common primary bone cancer which exhibits cancerous osteoblastic differentiation and malignant osteoid in patients. OS is generally very aggressive in nature with a high mortality rate and poor prognosis rate. Especially, OS mainly affects the adolescence children (5~15 years). Surgical resection technique was commonly employed to treat OS; however, surgical procedure implies the sacrifice of larger segment of bone and obligates complicated reconstruction. At present, chemotherapy (pre- and post-operative) is used as a standard treatment protocol for OS. However, drugs used in the treatment of OS induce high toxicity to normal tissues including anaemia, neutropenia, thrombocytopenia, and heart damage which further reduce the survival rate of OS patients. Therefore, there is an urgent need to develop a new therapeutic approach for the treatment of OS such that it induce maximum cell killing effect in tumor cells while sparing the healthy bone cells.

¹Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, 250021, China.
²Department of Urology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, 250021, China.
³Department of Orthopaedics, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, 250021, China. Correspondence and requests for materials should be addressed to R.-j.F. (email: rongjiefeng867@gmail.com)
In this regard, cisplatin (CDDP), a potent anticancer drug is often indicated for the treatment of OS. CDDP binds to DNA and causes DNA cross linking which triggers cell apoptosis when repair proves unsuccessful. Despite its potent anticancer effect, the therapeutic effect of CDDP has been limited by serious side effects such as nephrological and neurological toxicities. Nephrotoxicity is a major cause of CDDP associated acute and chronic morbidity, while neurotoxicity is cumulative-dose dependent. Despite the associated side effects, one of the major concerns is the rapid inactivation of the drug through non-specific protein binding in the blood stream, resulting in less therapeutic efficacy and undesirable side effects.

Formulating CDDP into polymeric nanoparticles is expected to reduce the associated side effects while at the same time would increase the therapeutic efficacy. NPs are able to improve the circulation of their encapsulated drugs in the blood compared to free drug. Thus, drug efficacy can be greatly increased without a subsequent increase in collateral damage to healthy tissues. In this regard, dextran (DX) is one of the most popular candidates for the formation of polymeric micelles. DX is highly biocompatible and biodegradable in nature which is consisting of α-(1→6) linked D glucose units with different ratios of linkages and branches. Due to the abundant presence of hydroxyl groups in the chemical structure, it is readily available for the conjugation. However, DX by itself could not self-assemble to form micelles as it lack the hydrophobic core (part). Therefore, in the present study we have conjugated DX with a biodegradable hydrophobic poly (lactic-co-glycolic acid) (PLGA). And, PLGA was conjugated with alendronate to increase the specificity of delivery system towards bone cancer cells. PLGA is one of the most common polymers used as carrier for drug delivery applications due to inherent biodegradability and low toxicity. Recently, it has been reported that PLGA-dextran block copolymer forms self-assembling nanoparticles and could be used as a carrier to deliver multiple anticancer agents.

Thus far, in the present study, we have fabricated PLGA-DX and PLGA-Alendronate block copolymer to develop self-assembled nanomicelles. The main aim was to load CDDP in the core of the micelles and to increase the therapeutic efficacy in osteosarcoma. We suppose that CDDP could be efficiently co-assembled with the hydrophobic segment of PLGA into the inner core of the polymeric micelles via intermolecular hydrophobic interactions. In general, hydrophobic interaction between the drug and the polymer block are one of the most important types of intermolecular forces involved in the nanoparticle formations. The physicochemical characterizations including size, shape, X-Ray diffraction, and release kinetics were performed. In vitro anticancer effect of free drug and nanoformulations were investigated on MG-63 osteosarcoma cancer cells. Cytotoxic effect of PLD/CDDP was further confirmed by apoptosis analysis and cell cycle analysis. Finally, in vivo antitumor efficacy study was performed in 6 week old xenograft tumor model.

Materials and Methods

Materials. Dextran (40kDa), sodium borohydride, and PLGA (molar ratio of DL-lactide/glycolide as 50/50, intrinsic viscosity of 0.61 dl/g) was purchased from Sigma-Aldrich, China. Cisplatin, Rhodamine B (RB), N-(3-Dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC), N-hydroxysuccinimide-de (NHS), 3-(4,5-Dimethyl-thiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) and Paraformaldehyde (PFA) were purchased from Sigma-Aldrich (China) Co. Ltd (Shanghai, China). All other chemicals were of analytical grade and used as obtained without further purification.

Fabrication of PLGA-Dextran sulphate polymer block. Carboxylic group-terminated PLGA was dissolved in 10 ml of anhydrous methylene chloride and to this organic solution, 150 mg of EDC was added and allowed to stir for 30 min, and followed by 75 mg of NHS was added and stirred for additional 10h at room temperature. The resulting PLGA-NHS was precipitated by adding ice cold diethyl ether. The precipitated mass was then subjected to washing and freeze drying process.

The PLGA-NHS (100 mg) was dissolved in DMSO and hexamethylene diamine was added and allowed the reaction for 24h. To this mixture, 120 mg of dextran was added and allowed the reaction to proceed for another 24h in the presence of sodium borohydride at inert conditions. The resulting PLGA-Dextran was precipitated by adding ice cold diethyl ether. The precipitated mass was then subjected to washing and freeze drying process.

The PLGA-Alendronate (PLGA-ALD) was synthesized as reported previously. Briefly, ALD was dissolved in 10% aqueous acetic acid solution, freeze dried, and resuspended with DMSO. To this solution, equimolar quantity of activated PLGA was added and allowed the reaction to continue for 24h. The final product was purified by dialysis against water and stored at cold temperatures.

Preparation of CDDP-loaded PLGA-Dextran NP. The PLD/CDDP NP was prepared by W/O/W double emulsion method. In brief, 0.5 mg of CDDP was dissolved in 10 ml of organic mixture (water/DMSO–3/2, v/v) and stirred for 10 min. 8 mg of PLGA-Dextran and 2 mg of PLGA-Alendronate was dissolved in an organic mixture consisting of dichloromethane and methanol (3/2, v/v) and stirred for 10 min. The drug solution was added to the polymer solution and immediately sonicated for 3 min using JY92-II ultrasonic cell disruptor from Ningbo Scientz Biotechnology Co. Ltd. (Ningbo, China). 4 mL of pluronic F-127 solution (0.1%) was added to the pre-emulsified solution and further sonicated for 5 min. The resulting PLD/CDDP NP was separated by centrifugation, washed, and dried. The drug loaded
nanoparticles were re-dispersed in water and showed excellent storage as well as colloidal stability (data not shown).

**Particle size and morphology examinations.** The size distribution of PLD nanoparticles were determined by quasi-elastic light scattering at 25°C, at an fixed angle of 90° using a Zeta Sizer 3000 HS (Malvern Instruments, UK). The samples were suitably diluted and all the measurements were performed in triplicate (n = 3).

The morphology of PLD NP was examined in JEOL JEM-200CX instrument (TEM) at an acceleration voltage of 200 kV. Samples were stained at room temperature with freshly prepared and sterile-filtered 1% (w/v) phosphotungstic acid aqueous solution. The samples were then placed in a carbon-coated copper grid and air dried prior to imaging.

**Physical characterization by XRD.** The crystalline state of CDDP in the formulation was determined by means of XRD-6000 X-ray diffractometer (XRD, Shimadzu, Japan) at a scan speed of 4°/min in the range of 3–30°.

**In vitro release study.** The release study of CDDP/PLD NP was performed by dialysis method. For this purpose, dialysis bag (Mol. Wt cut off 3000 Da) was used and the drug-loaded formulation (2 mg equivalent of CDDP) was placed in the dialysis membrane. The sealed dialysis membrane as placed in a Falcon tube containing 25 ml of release media and the entire assembly was kept in a shaking water bath which was maintained at 37°C and 100 rpm. At regular time intervals, 1 ml of external release medium was withdrawn and replaced with same amount of fresh medium. Amount of the drug released was then analyzed spectrophotometrically at 210 nm and percent cumulative release was plotted v/s time. The study was performed in triplicate (mean ± SD, n = 3).

**Cell culture and maintenance.** The human osteosarcoma cell line, MG-63 was purchased from West China Medical Center of Sichuan University, China and cultured in Eagle's Minimum Essential Medium containing 10% FBS and 1% Antibiotics (Penicillin (100 U/ml), streptomycin (100 μg/ml) and amphotericin B (2.5 mg/ml); Calbiochem, Germany). The cells were cultured at 37°C in a humidified incubator in an atmosphere of 95% oxygen and 5% carbon dioxide.

**Cytotoxicity assay.** MTT assay was performed to evaluate the cytotoxicity potential of free CDDP and PLD/CDDP formulations and dose-response curve was plotted. MG-63 cancer cell was used in the present study and cell survival was noted after the assay protocols. In brief, 1 x 10^4 cells were seeded in a 96-well plate in 100 μl of MEM medium and incubated for 24 h. When the cells reached 80% confluence, cells were treated with various concentrations of blank, free CDDP, and PLD/CDDP formulations (in media) and further incubated for 24 h. After 24 h, the derivatives in the medium were removed and 20 μl of MTT (5 mg/ml in MEM) was added and incubated for 4 h under normal growing conditions in the incubator. After 4 h, 100 μl of DMSO was added and placed for 30 min. After 30 min, optical density (OD) at 570 nm was measured using a plate reader. Cells without polymers were taken as control. A total of 8 replicates of 96-well plate was performed for each data (mean±S.D, n = 8). The IC50 value was determined using GraphPad Prism software (San Diego, CA).

**Cellular uptake study.** The cellular uptake study was performed using fluorescent PLD nanoparticles. For this purpose, rhodamine-B was used instead of CDDP. MG-63 cells were seeded at a density of 2 x 10^4 cells in a 12-well plate and incubated for 24 h. Cells were exposed with 5 μg/ml of rhodamine-B loaded PLD nanoparticles (in media) and incubated for 2 h. Cells were washed twice with PBS and fixed with 4% paraformaldehyde solution for 15 min. Cells were then viewed under confocal laser scanning microscopy.

**Apoptosis analysis.** FACS analysis is considered to be a specific and objective method for quantitative determination of apoptosis. MG-63 cells were seeded at a density of 5 x 10^4 cells in a 6-well plate and incubated for 24 h. When the cells reached 80% confluence, cells were treated with free CDDP and PLD/CDDP formulations (1 μg/ml equivalent concentration) and further incubated for 24 h and 48 h, respectively. Following day, cells were harvested, washed, and incubated with a mixture of 0.25 mg/mL Annexin-V FITC and 10 mg/mL PI. The mixture was kept for 15 min at 37°C. Excess PI and AV-FITC fluorescence were then washed off and cells were measured by flow cytometry (FACS Calibur, BD Biosciences). A minimum of 10,000 events was counted per sample by flow cytometry. A minimum of 4 replicates has been done (mean ± S.D, n = 4).

**Cell cycle analysis.** MG-63 cells were seeded at a density of 5 x 10^4 cells in a 6-well plate and incubated for 24 h. When the cells reached 80% confluence, cells were treated with free CDDP and PLD/CDDP formulations (1 μg/ml) and further incubated for 24 h. The cells were harvested, and the cell pellets were washed twice with PBS buffer and fixed in 75% ethanol solution at 4°C. Cells were resuspended in PBS containing 5 mg/mL PI and 50 mg/mL deoxyribonuclease-free ribonuclease A. This suspension was
incubated in dark atmosphere for 25 min and then cell cycle patterns were analysed using flow cytometry. A minimum of 4 replicates has been done (mean ± S.D, n = 4).

**In vivo antitumor efficacy study.** The animal study was approved by ‘Institutional Animal Ethics Committee’, Shandong University, China. The animal was carried out in accordance to the protocol framed by Shandong University, China. The *in vivo* antitumor efficacy study was performed in a 6-weeks BALB/c nude mice model. For this purpose, 1 × 10^6 MG-63 osteosarcoma cancer cells were subcutaneously injected into the right flank of mice. When tumors reached 75–100 mm^3, animals were randomly divided into 4 groups with 8 mice in each group. Control, blank NP, CDDP, and PLD/CDDP were intravenously administered at a dose of 5 mg/kg of mice (CDDP equivalent) for 4 times during 2 weeks period. Subsequently, tumor volume was measured at specified time using vernier caliper in two dimensions. Tumor volume (V) was measured by the formula: \( V = \frac{L \times W^2}{2} \), wherein length (L) is the longest diameter and width (W) is the shortest diameter perpendicular to length. At the end point, mice were sacrificed and tumours from each group were removed, fixed with 10% formalin and subsequently immunohistochemical analysis was performed. The study was performed in 8 mice for each group (mean ± S.D, n = 8).

**Statistical analysis.** A 2-paired Student's t test with equal variance was adopted to test the significance of the observed differences between the study groups. All data were expressed as means ± standard deviations (SD). The value of P < 0.05 was set to be statistically significant.

**Results and Discussion**

Dextran are colloidal, hydrophilic and water soluble substances, which are inert in biological systems and do not affect cell viability. Due to these properties, dextran has been extensively used as a drug carrier system, including for antidiabetics, antibiotics, anticancer drugs, peptides and enzymes. They are usually biodegradable, biocompatible, non-immunogenic. Dextran has many hydroxyl groups, and the abundant hydroxyl groups along the chain facilitate a broad range of further chemical modifications. The modification of dextran itself was also reported by numerous researchers to enhance its value as a biomaterial and to deliver small molecules. In the present study, we have continued to explore the potential utility of dextran after introducing the hydrophobic PLGA side chain on the dextran backbone for the effective delivery of CDDP. Although there are few studies in which polymeric micellar carriers (based on ionic interaction) have been developed however, ionic complex-based carriers lack the sufficient stability in the blood circulation. Whereas PLGA-DS nanoparticles has been expected to improve the systemic stability of drug in the systemic circulation. Moreover, presence of alendronate in the nanoparticle structure was expected to guide the nanoparticles towards the bone cancer cells.

**Characterization of PLGA-DS polymer.** The PLGA-DX polymer block was fabricated by the reaction between amine terminated-PLGA block and activated DS polymer block. The PLGA-DX was loaded with CDDP using a self-assembling process where in the drug was loaded in the core of the polymeric micelles (Fig. 1). The critical micelle concentration (CMC) of the Dex-PLGA was measured using pyrene as a hydrophobic fluorescent probe. The I1 and I3 of pyrene increased simultaneously while the I3 of pyrene increased significantly than that of I1, which led to the decreased of I1/I3 ratio quickly as the concentration of PLGA-DS polymer increased. The CMC of PLD was observed to be ~50 μg/mL (data not shown); indicating its excellent thermodynamic stability in the solution. Lower CMC value of a polymer is a indication of its ability to self-assemble in the aqueous medium.

**Characterization of PLD/CDDP.** The particle size of PLD/CDDP was studied using dynamic light scattering technique (DLS). DLS analysis showed an average size of ~180 nm with a narrow polydispersity index (PDI~0.24) (Fig. 2a). The mean size of nanoparticle was below <200 nm which is in the range of tumor vasculature permeation, suggesting that PLD/CDDP cold effectively accumulate in the solid tumours via enhanced permeation and retention (EPR) effect. Such characteristics of nanosystem could potentially increase the chemotherapeutic efficacy of anticancer drugs. The drug loading capacity of CDDP was studied spectrophotometrically. The PLD micelles showed a high entrapment efficiency of >90% with a high loading capacity of 28.5% w/w.

TEM analysis was performed to confirm the morphology of nanoparticle as well as to quantify the particle size (Fig. 2b). TEM could easily differentiate the regions of different materials, for example hydrophobic core and hydrophilic shell. TEM image showed a clear, perfect core-shell type spherical polymeric nanoparticles which are uniformly dispersed on the copper grid. The core-shell structure was clearly visible with ore being more electron dense than the shell which is greyish in colour. Moreover, TEM size was consistent with the size measured from DLS analysis.

The physical characterization of CDDP was investigated using X-Ray diffraction techniques (Fig. 2c) As seen, CDDP presents a numerous diffraction pattern indicating its high crystalline nature. Whereas, no diffraction peaks were identified in the PLD/CDDP formulation indicating that drug was efficiently loaded in the delivery system. These results indicated that the CDDP could be dispersed with the amphiphilic PLGA-DS and existed as amorphous or molecular state in PLD.

---

www.nature.com/scientificreports/
In vitro drug release. The drug release profile of CDDP from PLD/CDDP micelles was studied in phosphate buffered saline (PBS~7.4pH) at 37°C. As expected, CDDP suspension rapidly released from the dialysis membrane and 100% drug released within 10h of release period. PLD/CDDP micelles however controlled the release of drug over 48h in a gradual manner (Fig. 2d). Nevertheless, two phase of release was visible; first, nearly 50% of drug released within in 12h of study period (fast initial release) whereas rest of the drug gradually released up to 48h. The initial release of drug was due to the dissolution of drug which is poorly entrapped in the micelles. The slower release of PLD micelles could be the result of the diffusion of the drug loaded in the micelles core. It could be safely expected that CDDP could be slowly released in plasma (limited release) under normal physiological conditions (pH = 7.4), while, quickly released at the solid tumor site (pH = 5.5). Thus, the drug concentration in plasma could be kept at a relatively stable level to guarantee enough amount of drug would reach the tumor tissues. Model fitting of the drug release kinetics showed best fit for Higuchi model with r² value of 0.9845, suggesting that more than one mechanism was involved in the release of drug.

Cytotoxicity assay. In vitro cytotoxicity of blank NP, free CDDP, and PLD/CDDP was evaluated by means of 3-(4,5-dimethylthiazol-2-yl)- 2,5-diphenyltetrazolium bromide (MTT) assay. At first, cytotoxicity of blank NP was determined by treating the cancer cells with increasing concentration of nanoparticles (Fig. 3a). Results clearly showed that blank NP has no serious effect on the viability of cancer cells. The cell viability remained more than 90% even when treated with maximum concentration of blank NP. The excellent biocompatibility of block copolymer-based nanomaterials is ideal for cancer targeting. Followed, cytotoxicity effect of free drug and drug-loaded formulations were investigated on MG-63 cancer cells (Fig. 3b). Results showed significant differences (p < 0.05) in cytotoxicity potential between free drug and PLD/CDDP. Although, both the formulations exhibited a concentration-dependent cytotoxic effect, however PLD/CDDP exhibited a superior anticancer effect than that of free CDDP. The moderate cell toxicity effect of CDDP was consistent with its high IC50 value (~3.89 μg/ml) whereas PLD/CDDP exhibited a low IC50 value of 1.26μg/ml. The superior cytotoxicity of PLD/CDDP was mainly attributed to the sustained release of drug from the hydrophobic core of micelles to cancer cells. These studies demonstrate the cytotoxicity effect of CDDP-loaded materials and highlight their ability to deliver drug and effectively disrupt the growth of osteosarcoma cells.

Cellular uptake analysis of PLD nanocarrier. The cellular uptake of free drug and drug-loaded carrier was performed in MG63 cancer cells. As seen (Fig. 3c), CDDP/PLD showed significantly (p < 0.05) higher cellular than compared to that of free CDDP. The higher cellular uptake of nanocarrier would result in higher cytotoxic effect. Confocal laser scanning microscope (CLSM) was used to study the

Figure 1. Schematic synthesis of poly (lactic-co-glycolic acid) (PLGA)-dextran sulphate (DS) block copolymer. The CDDP and PLGA-DS self-assembled to forms a polymeric nanoparticles in which PLGA forms the core and DS forms the outer surface.
Figure 2. Physicochemical characterization of PLD/CDDP nanoparticles. (a) Size distribution analysis of PLD/CDDP evaluated using zetasizer, (b) TEM images of PLD/CDDP, (c) X-Ray diffraction analysis of free CDDP and PLD/CDDP. (d) In vitro release profile of CDDP from PLD/CDDP nanoparticles. The study was performed in phosphate buffered saline (pH 7.4) at 37°C. Data are expressed as standard deviation of the mean and n = 3. *p < 0.05 and **p < 0.01 is the statistical difference between tumor volume of CDDP and CDDP/PLD treated group.

Figure 3. Cytotoxicity analysis of (a) blank nanoparticles (b) free CDDP and PLD/CDDP in MG63 osteosarcoma cancer cell. The cytotoxicity analysis was performed by MTT assay after 24h incubation. Untreated cells were considered as control. (c) Cellular uptake of free CDDP and CDDP/PLD in MG63 cancer cells. (d) Confocal microscopy images demonstrating cellular internalization of PLD nanoparticles in MG63 cells. Data are expressed as standard deviation of the mean and n = 8. *p < 0.05 is the statistical difference between the cytotoxicity and cellular uptake of CDDP and CDDP/PLD treated group.
cellular distribution of PLD nanoparticles in cancer cells. For this purpose, CDDP was replaced with rhodamine-B as a fluorescent dye. The nucleus was stained with DAPI and indicated with blue colour. As seen from Fig. 3d, PLD NP was mainly distributed in the cytosolic region indicating a typical endocytosis-mediated receptor uptake. The red fluorescence was clearly observed on the periphery of cancer cells. From these results, it could be construed that the high cytotoxic effect of PLD/CDDP was attributed to endocytosis-cellular uptake wherein the NP was first located in the acidic organelles from where it will translocate to the nuclear region (after releasing from the delivery system)\(^26\).

**Apoptosis analysis.** To elucidate the mechanism of cell death and to confirm the potential of nanoparticles in inducing apoptosis, cells were stained with Annexin V and propidium iodide (PI). Annexin V binds to the phosphatidylserine which are generally present in the outer cell surface of apoptotic cells. PI stains the nucleus of late apoptotic and necrotic cells. As seen from Fig. 4, significant proportion of cells (\(p < 0.01\)) was present in the early and late apoptotic chambers after treatment with either free CDDP or PLD/CDDP. Moreover, time-dependent apoptosis of cancer cells were observed after the treatment. Consistent with the cytotoxicity assay, PLD/CDDP exhibited a significant apoptosis of MG63 cells compared to that of free CDDP. For example, ~25% of cells were in early apoptosis phase after PLD/CDDP treatment comparing to ~15% for free CDDP after 48h incubation. Similarly, PLD/CDDP exhibited ~30% of late apoptosis cells comparing to only ~8% for free drug treatment. Therefore it is clear that nanoparticulate formulation of CDDP remarkably increased the therapeutic performance of anticancer drug.

**Cell cycle analysis.** The influence of CDDP on the cell cycle progression was investigated by means of flow cytometry (Fig. 5). The results clearly showed that CDDP induced a typical G2/M phase arrest in MG63 cancer cells. Importantly, PLD/CDDP exhibited a significantly (\(p < 0.01\)) higher G2/M phase arrest in this cancer cell than comparing to free CDDP. It can be seen that nearly 2-fold higher G2/M arrest was observed in case of PLD/CDDP treated group (~60%). At the same time, cells in the G0/G1 phase decreased significantly (\(p < 0.01\)). This would result in enhanced cancer cell death. It has been reported that CDDP induce programmed cell death by inhibiting cells at G2 phase of cell cycle\(^27,28\). Therefore, nanoformulations of CDDP would be much superior in acting on different phases of cancer cell cycle.

**In vivo anticancer efficacy study.** In vivo antitumor efficacy of different formulations was investigated in MG-63 cancer cell bearing xenograft tumor model. As seen from Fig. 6, tumor volume constantly expanded from ~100 mm\(^3\) to ~2300 mm\(^3\) at the end of 24 days in the untreated mice group. Consistently,
tumor volume gradually increased in the blank NP treated group indicating that material comprising the vector barely had physiological activity (~2250 mm³). Free CDDP exhibited considerable tumor inhibiting capacity with final tumor volume of ~1400 mm³. The obvious delay in the tumor growth was mainly attributed to the strong antitumor effect of CDDP in the xenograft model. Among all the mice groups, PLD/CDDP exhibited a most significant (p < 0.01) anti-tumor activity with maximum tumor growth inhibition. The final tumor volume in PLD/CDDP treated group was ~700 mm³ indicating its superior anticancer efficacy in osteosarcoma. The superior antitumor effect of PLD/CDDP was attributed to the sustained release of drug from the nanosystem, possible enhanced tumor distribution of drugs, and induction of cell apoptosis 39,40.

Safety analysis. Body weight change was an indicator of systemic toxicity, which was simultaneously measured. Body weight of mice in control, blank NP and PLD/CDDP did not differ greatly and kept

Figure 5. Cell cycle analysis of MG63 cancer cells after treatment with free CDDP and PLD/CDDP for 24 h. The respective cell percentages in G2/M and G0/G1 phases are presented in the bar graph. Data are expressed as standard deviation of the mean and n = 4. **p < 0.01 is the statistical difference between G2/M phase expression of CDDP and CDDP/PLD treated group.

Figure 6. In vivo antitumor efficacy of free CDDP and PLD/CDDP in MG-63 cancer cell bearing tumor xenograft model. The mice were injected with cancer cell on the right flank and the treatment was started when the tumor volume reached ~100 mm³. The formulations were intravenously administered 4 times during first 12 days and tumor volume was measured using vernier caliper. (a) Tumor volume (b) body weight index. Data are expressed as standard deviation of the mean and n = 8. *p < 0.05 and **p < 0.01 is the statistical difference between tumor volume of CDDP and CDDP/PLD treated group.
constant (or increased slightly). However, free CDDP significantly decreased the body weight of mice indicating its severe drug-related systemic cytotoxicity to normal healthy tissues. Our result is consistent with the previously published report where CDDP was reported to show severe toxicity. It has been reported that free CDDP is associated with various side effects such as nephrotoxicity, myelosuppression, neurotoxicity, nausea, and emesis.

**Immunohistochemical analysis.** To determine the biological effects of free CDDP and PLD/CDDP, tumors were extracted from the sacrificed mice, fixed with 10% formalin, and subjected to vessel marker (CD31) and cellular proliferation (Ki67) assays. CD31 is a transmembrane glycoprotein and a platelet endothelial cell adhesion molecule that recognizes newly formed vasculature. Ki67 is involved in regulation of cell cycle and highly expressed in proliferating cells and is regarded as a one of the most prominent markers of cell proliferation or cell apoptosis. As shown in Fig. 7, marked reduction in the number of CD31 stained tumor blood vessels were observed in PLD/CDDP treated mice group. Similarly, Ki67 staining intensity was remarkably decreased in the formulation treated group. Therefore, decrease in the expression of CD31 and Ki67 is a clear indication of the superior therapeutic efficacy of PLD/CDDP nanoformulations.

Overall, proposed system has been shown to increase the therapeutic efficacy of CDDP in MG63 bone cancer cell bearing tumor xenograft model. The superior therapeutic action of present system was attributed to the two factors including the systemic stability of delivery system wherein it can avail the

---

**Figure 7. Immunohistochemistry studies performed in tumor samples.** The expression level of CD31 and Ki67 apoptosis markers were investigated in extracted tumor samples.
EPR effect and secondly the presence of alendronate moiety on the nanoparticle surface which has strong affinity towards the bone cancer cells. Therefore, the present delivery system is superior to other delivery carriers in terms of its tumor targeting potential\(^\text{11,35}\). Further studies are warranted to prove the superior antitumor efficacy of PLD therapeutic system.

**Conclusion**

In conclusion, we demonstrated in this study that poly (lactic-co-glycolic acid)-dextran sulphate (PLD)-based nanodelivery system remarkably enhanced the anticancer potential of CDDP in osteosarcoma cells. A niosized CDDP-loaded PLGA-DX nanoparticle (PLD/CDDP) with a mean diameter of ~180 nm was successfully developed. The PLD nanocarrier controlled the release rate of CDDP up to 48h. In vitro cytotoxicity assay showed a superior anticancer effect for PLD/CDDP and with an appreciable cellular uptake via endocytosis-mediated pathways. Furthermore, PLD/CDDP exhibited significant apoptosis of MG63 cancer cells compared to that of free CDDP. Approximately ~25% of cells were in early apoptosis phase after PLD/CDDP treatment comparing to ~15% for free CDDP after 48h incubation. Similarly, PLD/CDDP exhibited ~30% of late apoptosis cells compared to only ~8% for free drug treatment. PLD/CDDP exhibited significantly higher G2/M phase arrest in MG63 cells than compared to free CDDP with a nearly 2-fold higher arrest in case of PLD/CDDP treated group (~60%). Importantly, PLD/CDDP exhibited a most significant anti-tumor activity with maximum tumor growth inhibition. The final tumor volume in PLD/CDDP treated group was ~700 mm\(^3\) indicating its superior anticancer efficacy in osteosarcoma. The superior inhibitory effect was further confirmed by a marked reduction in the number of CD31 stained tumor blood vessels and decrease in the Ki67 staining intensity for PLD/CDDP treated animal group. Overall, CDDP-loaded PLD formulations could provide a promising and most effective platform in the treatment of osteosarcoma.

**References**

1. Ritter, J. & Bielack, S. S. Osteosarcoma. *Ann. Oncol.* **21**, 320–325 (2010).
2. Mankin, H. J., Mankin, C. J. & Simon, M. A. The hazards of the biopsy, revisited. Members of the Musculoskeletal Tumor Society, *J. Bone Joint Surg. Am.* **78**, 656–63 (1996).
3. Kufe, D. W., Pollock, R. E., Weishebal, R. R., Bast, R. C., Gansler, T. S., Holland, J. F. & Frei E. *Holland-Frei Cancer Medicine*, 6th ed., B. C. Decker (2003).
4. PosthumDeBoer, J., van Royen, B. & Helder, M. Mechanisms of therapy resistance in osteosarcoma: a review. *Oncol. Discovery* **1**, 8–15 (2013).
5. Luekte, A., Meyers, P. A., Lewis, I. & Juergens, H. Osteosarcoma treatment-where do we stand? A state of the art review, *Cancer Treat. Rev.* **40**, 523–532 (2014).
6. Horie, T. et al. Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway, *Cardiovasc. Res.* **87**, 656–664 (2010).
7. Longhi, A., Errani, C., De Paolis, M., Mercuri, M. & Bacci, G. Primary bone osteosarcoma in the pediatric age: State of the art. *Cancer Treat. Rev.* **32**, 423–36 (2006).
8. Yanand, X. & Gemeinhart, R. A. Cisplatin delivery from poly(acrylic acid-co-methyl methacrylate) microparticles, *Cancer Treat. Rev.* **24**, 265–81 (1998).
9. Crtitkovic, E. Cumulative toxicities from cisplatin therapy and current cytoprotective measures. *Cancer Treat. Rev.* **24**, 265–81 (1998).
10. Van Leeuwen, B. L., Kamps, W. A., Jansen, H. W. B. & Hoekstra, H. J. The effect of chemotherapy on the growing skeleton. *Cancer Treat. Rev.* **26**, 363–76 (2000).
11. Severson, S. & Tomalia, D. A. The effect of chemotherapy on the growing skeleton, *Adv. Drug Deliv. Rev.* **57**, 2106–2129 (2005).
12. Mitra, S., Gaur, U., Ghosh, P. C. & Maitra, A. N. Tumor targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier, *J. Control. Release* **74**, 317–323 (2001).
13. Yang, J. et al. The biocompatibility of fatty acid modified dextran-amine conjugate gene delivery vector, *Biomaterials* **33**, 604–13 (2012).
14. Agarwal, A., Gupta, U., Asthana, A. & Jain, N. K. Dextran conjugated dendritic nanoconstructs as potential vectors for anticancer agent, *Biomaterials* **30**, 3588–96 (2009).
15. Du, Y. Z., Weng, Q., Yuan, H. & Hu, F. Q. Synthesis and antitumor activity of stearate-dextran micelles for intracellular doxorubicin delivery, *ACS Nano* **4**, 6894–902 (2010).
16. Bachelder, E. M. et al. In vitro analysis of acetylated dextran microparticles as a potent delivery platform for vaccine adjuvants, *Mol. Pharm.* **7**, 826–35 (2010).
17. Liu, P., Sita, J. Q. & Li, W. S. High tolerated paclitaxel nano-formulation delivered by poly (lactic-co-glycolic acid)-dextran micelles to efficient cancer therapy, *Nanomedicine: Nanotechnology, Biology, and Medicine* **11**, 855–866 (2015).
18. Pignatello, R. et al. A novel biomaterial for osteotropic drug nanocarriers: synthesis and biocompatibility evaluation of a PLGA-ALG conjugate, *Nanomedicine* **4**, 161 (2009).
19. Du, Y. Z., Weng, Q., Yuan, H. & Hu, F. Q. Synthesis and antitumor activity of stearate-dextran micelles for intracellular doxorubicin delivery, *ACS Nano* **4**, 6894–902 (2010).
20. Shahin, M., Safaei-Nikouei, N. & Lavasanifar, A. Polymeric micelles for pH-responsive delivery of cisplatin. *J. Drug Target* **22**, 629–637 (2014).
21. Eno, K. et al. Tumor-targeted chemotherapy with the nanopolymer-based drug NC-6004 for oral squamous cell carcinoma, *Cancer Sci.* **104**, 369–374 (2013).
22. Dhule, S. S. et al. The combined effect of encapsulating curcumin and C6 ceramide in liposomal nanoparticles against osteosarcoma, *Mol. Pharm.* **11**, 417–27 (2014).
23. Yanand, X. & Gemeinhart, R. A. Cisplatin delivery from poly(acrylic acid-co-methyl methacrylate) microparticles. *J. Control. Release* **106**, 198–208 (2005).
24. Song, Z. et al. Curcumin-loaded PLGA-PEG-PLGA triblock copolymeric micelles: Preparation, pharmacokinetics and distribution in vivo, *J. Colloid Interface Sci.* **354**, 116–123 (2011).
25. Altnabias, A., Lee, S. J., Rajasekaran, S. A., Schneider, J. P. & Pochan, D. J. Encapsulation of curcumin in self-assembling peptide hydrogels as injectable drug delivery vehicles, *Biomaterials* **32**, 5906–5914 (2011).
26. Ramasamy, T. et al. pH sensitive polyelectrolyte complex micelles for highly effective combination chemotherapy, J. Mat. Chem. B, 2, 6324–6333 (2014).
27. Jamieson, E. R. & Lippard, S. J. Structure, recognition, and processing of cisplatin-DNA adducts, Chem. Rev. 99, 2467 (1999).
28. Dhar, S., Gu, F. X., Langer, R., Farokhzad, O. C. & Lippard, S. J. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug–PLGA–PEG nanoparticles, Proc. Natl. Acad. Sci. USA 105, 17356 (2008).
29. Moghimi, S. M., Hunter, A. C. & Murray, J. C. Long-circulating and target-specific nanoparticles: theory to practice, Pharmacol. Rev. 53, 283 (2001).
30. Tan, M. L., Friedhuber, A. M., Dunstan, D. E., Choong, P. F. M. & Dass, C. R. The performance of doxorubicin encapsulated in chitosan-dextran sulphate microparticles in an osteosarcoma model. Biomaterials 31, 541–51 (2010).
31. Cao, H., Wang, Y. & He, Y. Codelivery of Sorafenib and Curcumin by Directed Self-Assembled Nanoparticles Enhances Therapeutic Effect on Hepatocellular Carcinoma, Mol. Pharm. 12, 922–931 (2015).
32. Li, Y., Lim, S. & Ooi, C. P. Fabrication of Cisplatin-Loaded Poly(lactide-co-glycolide) Composite Microspheres for Osteosarcoma Treatment, Pharm. Res. 29, 756–769 (2012).

Acknowledgements
This research was supported by grants from the National Natural Science Foundation of China (No. 81300964), the China Postdoctoral Science Foundation (No. 2013M531611), the China Postdoctoral Science Foundation (No. 2014T70648), Science and Technology Development Plan Project of Shandong Province (No. 2014GSF118092 and No. 2013GSF11850 and the Natural Science Foundation of Shandong Province (No. ZR2011HM054 and No. ZR2014HQ041).

Author Contributions
P.L. and L.S. were involved in the preparation and preliminary characterization of formulaitons. D.S.Z., P.Z. and Y.H.W. carried out all the in vitro assays. D.L. and Q.H.L. participated in all the animal handling as well as cellular assay. R.J.F. has designed and written the entire manuscript.

Additional Information
Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Liu, P. et al. Development of Alendronate-conjugated Poly (lactic-co-glycolic acid)-Dextran Nanoparticles for Active Targeting of Cisplatin in Osteosarcoma. Sci. Rep. 5, 17387; doi: 10.1038/srep17387 (2015).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
Retraction: Development of Alendronate-conjugated Poly (lactic-co-glycolic acid)-Dextran Nanoparticles for Active Targeting of Cisplatin in Osteosarcoma

Ping Liu, Liang Sun, Dong-sheng Zhou, Peng Zhang, Yong-hui Wang, Dong Li, Qing-hu Li & Rong-jie Feng

*Scientific Reports* 5:17387; doi: 10.1038/srep17387; published online 01 December 2015; updated on 16 September 2016

The authors of this Article have requested that it be retracted. During attempts to scale up the experiments for clinical studies, we could not reproduce the apoptosis (Figure 4) and cell cycle distribution results reported in the paper. We carried out a detailed intra-departmental investigation and found that the equivalent concentrations of cisplatin (CDDP) in the nanoparticles (PLD) had been miscalculated, and that the MG63 cells were cross-contaminated, leading to significant errors in the experimental results.

All the authors recognize that these errors have affected the validity of the Article and have agreed to retraction. The authors apologize for their carelessness.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2016